FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / closing-letter-to-client.docx
closing-letter-to-client.docx · 1013-00002

Parties

HARKNESS LLP
Secretary Genome Dx Therapeutics Inc
Genome Dx Therapeutics Inc
Delaware General Corp
General Corp
California Corp
Equity Inc
Cavanaugh LLP

Dates

April 22, 2024
April 12, 2024
April 8, 2024
April 9, 2024
April 19, 2024
April 5, 2024
December 31, 2023
April 17, 2024
March 29, 2024
April 10, 2024

Amounts

$40,000,000
$22,000,000
$12,000,000
$6,000,000
$50,000,000
$4.1451
$200,000,000
$20,000,000
$28,000,000
$7,000,000

Obligations

All outstanding principal and accrued but uncapitalized interest shall be due and payable on the Maturity Date, unless the Notes have been previously converted or repaid in accordance with their terms
The outstanding principal and all accrued and unpaid interest under the Notes shall automatically convert into shares of the equity securities issued in a Qualified Financing
If the Notes have not been previously converted pursuant to a Qualified Financing, each holder of a Note shall have the right, at the Maturity Date, to elect either (A) conversion of its Note into shares of the Company's common stock at the Valuation Cap Price of $4
Pursuant to Rule 503 of Regulation D under the Securities Act, the Company is required to file a notice on Form D with the U
In addition to the federal Form D filing, the Company is required to make notice filings under applicable state "blue sky" laws in connection with the private placement
A notice filing under Section 25102(f) of the California Corporations Code is required to be made with the California Department of Financial Protection and Innovation